Clinical Correlates of Vitamin D Deficiency in Established Psychosis
Overview
Authors
Affiliations
Background: Suboptimal vitamin D levels have been identified in populations with psychotic disorders. We sought to explore the relationship between vitamin D deficiency, clinical characteristics and cardiovascular disease risk factors among people with established psychosis.
Methods: Vitamin D levels were measured in 324 community dwelling individuals in England with established psychotic disorders, along with measures of mental health, cardiovascular risk and lifestyle choices. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D (25-OHD) levels below 10 ng/ml (equivalent to <25 nmol/L) and "sufficient" Vitamin D as above 30 ng/ml (>50 nmol/L).
Results: The mean 25-OHD serum level was 12.4 (SD 7.3) ng/ml, (range 4.0-51.7 ng/ml). Forty nine percent (n = 158) were vitamin D deficient, with only 14 % (n = 45) meeting criteria for sufficiency. Accounting for age, gender, ethnicity and season of sampling, serum 25-OHD levels were negatively correlated with waist circumference (r = -0.220, p < 0.002), triglycerides (r = -0.160, p = 0.024), total cholesterol (r = -0.144, p = 0.043), fasting glucose (r = -0.191, p = 0.007), HbA1c (r = -0.183, p = 0.01), and serum CRP levels (r = -0.211, p = 0.003) and were linked to the presence of metabolic syndrome.
Conclusions: This is the largest cross sectional study of serum 25-OHD levels in community dwelling individuals with established psychosis, indicating a high level of vitamin D deficiency. Lower vitamin D levels are associated with increased cardiovascular disease risk factors and in particular metabolic syndrome. Further research is needed to define appropriate protocols for vitamin D testing and supplementation in practice to see if this can improve cardiovascular disease risk.
Trial Registration: ISRCTN number is ISRCTN58667926 Date of registration: 23/04/2010.
Huang Q, Hu Z, Zheng Q, Mao X, Lv W, Wu F Phenomics. 2024; 4(2):91-108.
PMID: 38884061 PMC: 11169348. DOI: 10.1007/s43657-023-00115-z.
Hatzimanolis A, Tosato S, Ruggeri M, Cristofalo D, Mantonakis L, Xenaki L Transl Psychiatry. 2024; 14(1):36.
PMID: 38238289 PMC: 10796745. DOI: 10.1038/s41398-024-02750-0.
Jia N, Dong L, Lu Q, Li X, Jin M, Yin X BMC Psychiatry. 2023; 23(1):692.
PMID: 37743466 PMC: 10518911. DOI: 10.1186/s12888-023-05196-8.
Jaholkowski P, Hindley G, Shadrin A, Tesfaye M, Bahrami S, Nerhus M Schizophr Bull. 2023; 49(6):1654-1664.
PMID: 37163672 PMC: 10686370. DOI: 10.1093/schbul/sbad063.
Characterization of Hip Fractures Among Adults With Schizophrenia in Ontario, Canada.
Ansari H, Jaglal S, Cheung A, Kurdyak P JAMA Netw Open. 2023; 6(4):e2310550.
PMID: 37115547 PMC: 10148203. DOI: 10.1001/jamanetworkopen.2023.10550.